How well researched is Diabetes ReliefSM treatment?
The principles of Diabetes ReliefSM are also used in therapies known as Metabolic Activation Therapy (MAT) or Pulsatile Intravenous Insulin Therapy (PIVIT) or chronic intermittent intravenous insulin infusion Therapy (CIIIT). This potentially important therapy and its research began several years ago, but it has been lost as a mainstream approach of investigation and treatment in patients with diabetes. Currently clinical studies are under way, published articles and scientific papers featuring case studies have shown promising results.
Quoting Diabetes Relief’s White Paper published in 2018:
“The physiologic secretion of insulin by the pancreas is well established, as is the evidence that impaired oscillations of insulin play a significant role in the development of diabetes. Even though there are hundreds of teams developing molecules to manage the progression of the disease, the incidence and impact of diabetes continues to grow. It was this challenge that has led to the development of a novel therapeutic regimen that is producing superior outcomes by mimicking the body’s own method of regulating insulin.
Diabetes Relief’s patented treatment improves hepatic glucose process and is an effective program that is poised to transform the way diabetes is managed. Several clinical studies have shown this therapeutic approach to be safe and efficacious. The Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy was published in 2000. The purpose of this study was to assess the effects of pulsatile intravenous insulin therapy (PIVIT) on the progression of diabetic nephropathy in patients with type 1 diabetes mellitus (DM). This 18 month multicenter, prospective, controlled study involved 49 type 1 DM patients with nephropathy who were following the Diabetes Control and Complications Trial (DCCT) intensive therapy (IT) regimen. Of these, 26 patients formed the control group (C), which continued on IT, while 23 patients formed the treatment group (T) and underwent, in addition to IT, weekly PIVIT. Blood pressure in all patients was maintained below 140/90 mm Hg on antihypertensive medication, preferentially using angiotensin-converting enzyme (ACE) inhibitors. All study patients were seen in the clinic weekly for 18 months, had monthly HbA1c monitoring, as well as 24-hour urinary protein excretion and creatinine clearance (CrCl) determinations performed every 3 months. The HbA1c levels declined from 8.61% +/-0.33% to 7.68% +/-0.31% (P = .0028) in the T group and from 9.13% +/-0.36% to 8.19% +/-0.33% (P = .0015) in the C group during the study period. CrCl declined significantly in both groups, as expected, but the rate of CrCl decline in the T group (2.21 +/-1.62 mL/min/yr) was significantly less than in the C group (7.69 +/-1.88 mL/min/yr, P = .0343). The authors conclude that when PIVIT is added to IT in type 1 DM patients with overt nephropathy, it appears to markedly reduce the progression of diabetic nephropathy. The effect appears independent of ACE inhibitor therapy, blood pressure, or glycemic control.
Subsequent to these findings, other studies were conducted and published including Effect of Intensive Insulin Therapy on Progression of Overt nephropathy in Patients with Type 1 Diabetes Mellitus by researchers at the University of California, Davis. In this clinical trial investigators set out to assess the effects of chronic (long-term) intermittent intravenous insulin therapy (CIIIT) on the progression of overt nephropathy in patients with type 1 diabetes mellitus. This retrospective longitudinal three-center study of 31 patients with type 1 diabetes mellitus and overt nephropathy who were receiving intensive subcutaneous insulin therapy (four insulin injections daily) and weekly CIIIT. Study patients had follow-up consultations weekly for at least 12 months, monthly hemoglobin A1c (by high-performance liquid chromatography), and semiannual creatinine clearance determinations. The results showed hemoglobin A1c levels declined significantly from 8.6% +/-0.6% to 7.6 % +/-0.3% (P = 0.0062) during the study period, while the creatinine clearance remained essentially unchanged. The authors concluded that the addition of CIIIT to intensive subcutaneous insulin therapy in patients with type 1 diabetes mellitus seems to arrest or appreciably reduce the progression of overt diabetic nephropathy, as well as substantially improve their glycemic control.
By leveraging state-of-the-art technology and proprietary algorithms Diabetes Relief has developed and refined a therapeutic process that further improves upon the pioneering work in this field. Diabetes Relief utilizes the physiologic pattern of administration of insulin via intravenous infusions with FDA-approved devices and medications. These infusions are included as the centerpiece of a customized treatment plan that includes traditional recommendations for diet and exercise along with proprietary nutritional support.
While other treatments seek to control the symptom of hyperglycemia, Diabetes Relief reduces insulin resistance by re-sensitizing insulin receptors. The complications of diabetes are not due to a direct toxic effect of hyperglycemia but rather a failure of cells to replicate and replace aging cells. By addressing the impaired pancreatic insulin pulse, Diabetes Relief facilitates carbohydrate metabolism which enhances growth and repair of tissue beds throughout the body and thus dramatically reduces both hyperglycemia and diabetic complications. Current treatment modalities focus on controlling the symptom of hyperglycemia. The treatments have significant limitations in reversing the devastating complications that occur in progression of this disease. The literature is replete with detailed descriptions of cellular signals between the pancreases and liver which affect carbohydrate metabolism. Armed with this information, Diabetes Relief has developed a program to approximate normal physiologic signaling to restore insulin sensitivity. While others search for more ways to increase the availability of insulin that increases hyperinsulinemia and may ultimately desensitization and downregulate receptors, Diabetes Relief employs an alternate approach to improve the efficiency of insulin by providing a physiologic delivery. With the ever-growing epidemic of this disease, treatments need to go beyond control of hyperglycemia and address the core defects that have propelled this condition into a global health crisis.”
Copyright by Diabetes ReliefSM, 2018
Who may benefit from Diabetes ReliefSM treatment?
Diabetes Relief treatment may benefit patients that are unable to achieve a balanced glucose control because of severe hypoglycemic episodes due to hypoglycemia unawareness. Other Patients work with their endocrinologist and, despite vigorous attempts to control their glucose levels, are still experiencing diabetic complications. Those patients may benefit from the treatment as well.
It has been observed that the Diabetes ReliefSM treatment program can reduce hypoglycemic attacks (dangerously low blood sugar) by improving hypoglycemia unawareness and can reduce or delay many complications of diabetes such as damage to kidneys and eyes, abnormal blood pressure, painful neuropathy of the feet and legs, gastroparesis, and foot ulcers.
How soon can I expect improvement with Diabetes ReliefSM treatments?
With each session there appears to be a step-wise improvement in metabolic function. After the first 10 days of treatments patients usually report of better sleep quality and improved ability to concentrate. Patients also note higher energy levels and improved wound healing and a more balanced blood pressure. Often those with “brittle” diabetes notice an improvement in glucose control. However, other complications such as peripheral neuropathy, diabetic complications of the eye, kidney and heart. may take longer to see symptomatic improvements. Because each patient is different and may deal with multiple complications at the same time, improvement in some are noticed earlier than others. To support the continued healing and adaption progress a repeat treatment may be recommended in some cases depending on the symptoms and their severity.
What benefits have patients reported with Diabetes ReliefSM treatment?
- Improved sleep quality
- Improved cognitive abilities
- Improved blood sugar control.
- Reduced the severity of swings in blood sugar levels in patients with “brittle” diabetes.
- Restored hypoglycemia awareness.
- Decreased episodes of severe hypoglycemia by approximately 98 percent.
- Slowed progression of diabetic kidney and eye disease.
- Lowered high blood pressure in diabetic patients.
- Eliminated dizziness/ blackouts due to orthostatic hypotension.
- Accelerated wound healing.
- Improved heart metabolism.
- Improvement of peripheral neuropathy.
- Improvement of gastroparesis.
How does metabolic function improve with Diabetes ReliefSM treatment?
In contrast to usual insulin therapy, insulin pulses imitate the body’s own natural insulin release patterns and appear to enhance the liver’s ability to store, mobilize and utilize glucose. The higher level of insulin available to the liver with Diabetes ReliefSM treatments stimulates liver cells to synthesize glucokinase and other insulin-dependent enzymes necessary for normal dietary glucose processing and homeostasis.